Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$129.5MBeat by $16.4M
EPS$0.13Beat by $0.10
Revenue estimate$113.1M
EPS estimate$0.03

Next report

Oct 27, 2026 (in a month)
Revenue estimate$141.7M
EPS estimate$0.17

Financials

Q4 2025

Income statement

See full
Revenue$129.5M+81.5%
Gross profit$117.8M+82.8%

Balance sheet

See full
Cash & equivalents$43.2M-39.9%
Total debt$114.5M+3.6%
Total equity$189.5M+20.3%
Total assets$433.0M+24.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.56B+118%
Enterprise value$3.63B+117%
P/S9.5×+1.2×

Profitability

See full
Gross margin90.2%0.0pp

Returns & leverage

See full
Debt / equity0.6×-0.1×
Current ratio3.2×-1.0×

Segments

By segment

See full
Reportable Segment$129.5M+81.5%

FAQ

When did Arcutis Biotherapeutics, Inc. report Q4 2025 earnings?
Arcutis Biotherapeutics, Inc. (ARQT) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Arcutis Biotherapeutics, Inc.'s Q4 2025 revenue and EPS?
Arcutis Biotherapeutics, Inc. reported revenue of $129.5M and eps of $0.13 for Q4 2025.
Did Arcutis Biotherapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $113.1M by $16.4M. EPS beat the consensus estimate of $0.03 by $0.10.
How did Arcutis Biotherapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 81.5% from $71.4M a year earlier.
Where can I find Arcutis Biotherapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001787306-26-000017) and the 10-K periodic report (0001787306-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.